Cuervo M, Sanclemente G, Barrera L. Caracterización clínica, sociodemográfica y determinación del impacto en la calidad de vida de pacientes con dermatitis atópica de la ciudad de Medellín y su área metropolitana. Biomédica. 2021;41(4):676-91. https://doi.org/10.7705/biomedica.5978

Siegels D, Heratizadeh A, Abraham S, Binnmyr J, Brockow K, Irvine A, et al. Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis. Allergy. 2021;76(4):1053-76. https://doi.org/10.1111/all.14631

Luu L, Flowers R, Kellams A, Zeichner S, Preston D, Zlotoff B, et al. Apple cider vinegar soaks [0.5%] as a treatment for atopic dermatitis do not improve skin barrier integrity. Pediatr Dermatol. 2019;36:634–9. https://doi.org/10.1111/pde.13888

Bylund S, Kobyletzki L, Svalstedt M, Svensson Å. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2020;100(12):adv00160. https://doi.org/10.2340/00015555-3510

Maspero J, Motta N, Zhang J, Sanclemente G, Amador J, El Sayed M, et al. Epidemiology of adult patients with atopic dermatitis in AWARE 1: A second international survey. World Allergy Organ J. 2023;16(3):100724. https://doi.org/10.1016/j.waojou.2022.100724

Weidinger S, Beck L, Bieber T, Kabashima K, Irvine A. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. https://doi.org/10.1038/s41572-018-0001-z

von Kobyletzki L, Bornehag C, Breeze E, Larsson M, Boman C, Svenssonet Å. Factors associated with remission of eczema in children: a population-based follow-up study. Acta Derm Venereol. 2014;94(2):179-84. https://doi.org/10.2340/00015555-1681

Londoño A, Castro-Ayarza J, Kronfly A, Buitrago D, Samacá D. Epidemiología y uso de recursos de salud en dermatitis atópica en Colombia: análisis retrospectivo de datos del Registro Nacional de Salud de 2015 a 2020. Biomédica. 2023;43(1):107-20. https://doi.org/10.7705/biomedica.6666

Frazier W, Bhardwaj N. Atopic Dermatitis: Diagnosis and Treatment. Am Fam Physician. 2020;101(10):590-8.

Hadi H, Tarmizi A, Khalid K, Gajdács M, Aslam A, Jamshed S. The Epidemiology and Global Burden of Atopic Dermatitis: A Narrative Review. Life (Basel). 2021;11(9):936. https://doi.org/10.3390/life11090936

Sanclemente G, Hernández N, Chaparro D, Tamayo L, López A; Colombian Atopic Dermatitis Research Group. Epidemiologic features and burden of atopic dermatitis in adolescent and adult patients: A cross-sectional multicenter study. World Allergy Organ J. 2021;14(12):100611. https://doi.org/10.1016/j.waojou.2021.100611

Hernández-Mantilla N, Laignelet-Hernández H. Características clínicas, costos y necesidades insatisfechas en pacientes con dermatitis atópica leve, moderada y severa en Colombia. Dermatol Rev Mex. 2021;65(4):494-507. https://doi.org/10.24245/dermatolrevmex.v65i4.6599

Hernández-Mantilla N, Cárdenas-Rojas P, Picó J, Pareja-Zabala M. Dermatitis atópica: tratamiento y costos desde la perspectiva de expertos clínicos colombianos. Dermatol Rev Mex. 2020;64(5):528-34.

George S, Karanovic S, Harrison D, Rani A, Birnie A, Bath-Hextall F, et al. Interventions to reduce Staphylococcus aureus in the management of eczema. Cochrane Database Syst Rev. 2019;(10):CD003871. https://doi.org/10.1002/14651858.CD003871.pub3

Langer G, Meerpohl J, Perleth M, Gartlehner G, Kaminski-Hartenthaler A, Schünemann H. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Z Evid Fortbild Qual Gesundhwes. 2012;106(5):357-68. https://doi.org/10.1016/j.zefq.2012.05.017

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6. https://doi.org/10.1136/bmj.39489.470347.AD

Instituto de Evaluación Tecnológica en Salud - IETS. Manual metodológico. Participación y Deliberación. Bogotá D.C.: IETS; 2014. Disponible en: https://t.ly/5UgA9

Alonso-Coello P, Oxman A, Moberg J, Brignardello-Petersen R, Akl E, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089. https://doi.org/10.1136/bmj.i2089

Alonso-Coello P, Schünemann H, Moberg J, Brignardello-Petersen R, Akl E, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016. https://doi.org/10.1136/bmj.i2016

Schünemann H, Mustafa R, Brozek J, Santesso N, Alonso-Coello P, Guyatt G, et al. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. J Clin Epidemiol. 2016;76:89-98. https://doi.org/10.1016/j.jclinepi.2016.01.032

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editores). Cochrane Handbook for Systematic Reviews of Interventions. Versión 6.5; 2024. Disponible en: https://t.ly/e106q

Higgins JP, Altman D, Gøtzsche P, Jüni P, Moher D, Oxman A, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928

Shea B, Reeves B, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:i4008. https://doi.org/10.1136/bmj.j4008

Atkins D, Eccles M, Flottorp S, Guyatt G, Henry D, Hill S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4(1):38. https://doi.org/10.1186/1472-6963-4-38

Guyatt G, Oxman A, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94. https://doi.org/10.1016/j.jclinepi.2010.04.026

Dewidar O, Lotfi T, Langendam M, Parmelli E, Parkinson Z, Solo K, et al. Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance. BMJ Evid Based Med. 2023;28(3):189-96. https://doi.org/10.1136/bmjebm-2022-111962

Asociación Colombiana de Dermatología y Cirugía Dermatológica - AsoColDerma; Centro dermatológico Federico Lleras Acosta; Instituto de Evaluación Tecnológica en Salud - IETS. Guía de práctica clínica (GPC) para el diagnóstico y tratamiento de la dermatitis atópica en Colombia. Rev Asoc Colomb Dermatol Cir Dematol. 2018;28(4). https://doi.org/10.29176/2590843X.1508

Martín-Santiago A, Puig S, Arumi D, Rebollo P. Safety profile and tolerability of topical phosphodiesterase 4 inhibitors for the treatment of atopic dermatitis: A systematic review and meta-analysis. Current Ther Res Clin Exp. 2022;100679:96. https://doi.org/10.1016/j.curtheres.2022.100679

Fahrbach K, Tarpey J, Bergrath E, Hughes R, Thom H, Neary M, et al. Crisaborole ointment, 2%, for treatment of patients with mild-to-moderate atopic dermatitis: systematic literature review and network meta-analysis. Dermatol Ther. 2020;10(4):681-94. https://doi.org/10.1007/s13555-020-00389-5

Paller A, Tom W, Lebwohl M, Blumenthal R, Boguniewicz M, Call R, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503. https://doi.org/10.1016/j.jaad.2016.05.046

Murrell DF, Gebauer K, Spelman L, Zane L. Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2a, vehicle-controlled, proof-of-concept study. J Drugs Dermatol. 2015;14:1108-12.

Bissonnette R, Pavel A, Diaz A, Werth J, Zang C, Vranic I, et al. Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy Clin Immunol. 2019;144(5):1274-89. https://doi.org/10.1016/j.jaci.2019.06.047

Fujita K, Yagi M, Moriwaki S, Yoshida M, Graham D. A phase 2b, randomized, double‐blind, multicenter, vehicle‐controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild‐to‐moderate atopic dermatitis. J Dermatol. 2021;48:1640-51.

Silverberg J, Tallman A, Ports W, Gerber R, Tan H, Zielinski M, et al. Evaluating the efficacy of crisaborole using the atopic dermatitis severity index and percentage of affected body surface area. Acta Derm Venereol. 2020;100(13):adv00170. https://doi.org/10.2340/00015555-3489

Yosipovitch G, Gold L, Lebwohl M, Silverberg J, Tallman A, Zane L. Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor. Acta Derm Venereol. 2018;98(5):484-9. https://doi.org/10.2340/00015555-2893

Schlessinger J, Shepard J, Gower R, Su J, Lynde C, Cha A, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to< 24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020;21(2):275-84. https://doi.org/10.1007/s40257-020-00510-6

Wu S, Wang H. Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized controlled trials. Postepy Dermatol Alergol. 2022;39:601-10.

Koskeridis F, Evangelou E, Ntzani E, Kostikas K, Tsabouri S. Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis. J Cutan Med Surg. 2022;26:613-21.

Simpson E, Paller A, Siegfried E, Boguniewicz M, Sher L, Gooderham M, et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(1):44-56. https://doi.org/10.1001/jamadermatol.2019.3336

Paller A, Siegfried E, Thaçi D, Wollenberg A, Cork M, Arkwright P, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282-93. https://doi.org/10.1016/j.jaad.2020.06.054

Kamal M, Kovalenko P, Kosloski M, Srinivasan K, Zhang Y, Rajadhyaksha M, et al. The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis. Clin Pharmacol Ther. 2021;110(5):1318-28. https://doi.org/10.1002/cpt.2366

Meher, B. R., Mohanty, R. R. & Padhy, B. M. Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials. J Dermatolog Treat 33, 2335–2343 (2022).

Drucker A, Morra D, Prieto-Merino D, Ellis A, Yiu Z, Rochwerg B, et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. JAMA Dermatol. 2022;158(5):523-32. https://doi.org/10.1001/jamadermatol.2022.0455

Li C, Sun X, Zhao K, Meng F, Li L, Mu Z, et al. Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis. Dermatology. 2022;238(4):725-35. https://doi.org/10.1159/000518541

Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis. Dermatol Ther. 2022;35:e15636.

Reich K, Teixeira H, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169-181. https://doi.org/10.1016/S0140-6736(21)00589-4

Blauvelt A, Teixeira H, Simpson E, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2021;157(9):1047-55. https://doi.org/10.1001/jamadermatol.2021.3023

Bakaa L, Pernica J, Couban R, Tackett K, Burkhart C, Leins L, et al. Bleach baths for atopic dermatitis: A systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE. Ann Allergy Asthma Immunol.12022;28(6):660-68.e9. https://doi.org/10.1016/j.anai.2022.03.024

Collier E, Sangar S, Shen A, Davis J. A closer look at bleach baths: evidence, tub size, and instructions. Dermatology. 2022;238:603-8.

Maleki-Yazdi K, Fog Heen A, Zhao I, Guyatt G, Suzumura E, Makhdami N, et al. Values and Preferences of Patients and Caregivers Regarding Treatment of Atopic Dermatitis (Eczema): A Systematic Review. JAMA Dermatol. 2023;159(3):320-30. https://doi.org/10.1001/jamadermatol.2022.6045

Yepes-Nuñez J, Guyatt G, Gómez-Escobar L, Pérez-Herrera L, Chu A, Ceccaci R, et al. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol. 2023;151(1):147-58. https://doi.org/10.1016/j.jaci.2022.09.020

Sánchez J. Adherence to allergen immunotherapy improves when patients choose the route of administration: Subcutaneous or sublingual. Allergol Immunopathol. 2015;43:436-41.

Sánchez J, Restrepo M, Diez S, Cardona R. Comparación del efecto clínico de la inmunoterapia en pacientes con asma alérgica según la edad y el patrón de sensibilización. Alergia Asma Inmunol Pediatr. 2014;23:6-14.

Oykhman P, Dookie J, Al-Rammahy H, de Benedetto A, Asiniwasis R, LeBovidge J, et al. Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2022;10(10):2657-66.e8. https://doi.org/10.1016/j.jaip.2022.06.044

Sánchez J, Sánchez M, Macías-Weinmann A, Barreto B, Ensina L, Uriarte-Obando S, et al. Systematic review about 10 interventions in dermatitis. A document from the Latin American Society of Allergy, Asthma, and Immunology. Rev Alerg Mex. 2019;66(4):426-55. https://doi.org/10.29262/ram.v66i4.636

Tsakok T, Marrs T, Mohsin M, Baron S, du Toit G, Till S, et al. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol. 2016;137(4):1071-8. https://doi.org/10.1016/j.jaci.2015.10.049

Domínguez O, Plaza A, Alvaro M. Relationship between atopic dermatitis and food allergy. Current Pediatr Rev. 2020;16:115-22.

Eigenmann P, Sicherer S, Borkowski T, Cohen B, Sampson H. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics. 1998;101:e8-e8.

Clement C, Ridd M, Roberts K, Santer M, Boyle R, Muller I, et al. Parents and GPs’ understandings and beliefs about food allergy testing in children with eczema: qualitative interview study within the Trial of Eczema allergy Screening Tests (TEST) feasibility trial. BMJ Open. 2020;10(11):e041229. https://doi.org/10.1136/bmjopen-2020-041229

Shi V, Bhutani T, Fonacier L, Deleuran M, Shumack S, Valdez H, et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol. 2022;87(2):351-8. https://doi.org/10.1016/j.jaad.2022.04.009

Gao D, Kahn J, Cohen S, Griffiths D, Fiumara K, Lam A, et al. Results of Switching From Tofacitinib to Upadacitinib in Patients With Atopic Dermatitis: A Retrospective Medical Record Review. Dermatitis. 2021;32(6):e165-e166. https://doi.org/10.1097/DER.0000000000000809

Reich A. Reliable assessment of atopic dermatitis severity: do we need more tools? Br J Dermatol. 2021;184:6-7.

Schmitt J, Langan S, Williams H, Network E. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol. 2007;120:1389-98.

Bożek A, Reich A. Assessment of intra-and inter-rater reliability of three methods for measuring atopic dermatitis severity: EASI, objective SCORAD, and IGA. Dermatology. 2017;233:16-22.

Silverberg J, Lei D, Yousaf M, Janmohamed S, Vakharia P, Chopra R, et al. Comparison of patient-oriented eczema measure and patient-oriented scoring atopic dermatitis vs eczema area and severity index and other measures of atopic dermatitis: a validation study. Ann Allergy Asthma Immunol. 2020;125(1):78-83. https://doi.org/10.1016/j.anai.2020.03.006

Li A, Zhang M, Yang Y, Zhang J, Xie X, Li X, et al. Patient-reported outcome (PRO) instruments for disease severity and quality of life in patients with atopic dermatitis: a systematic review of English and Chinese literature. Ann Transl Med. 2022;10(16):906. https://doi.org/10.21037/atm-22-3164

Stuart B, Howells L, Pattinson R, Chalmers J, Grindlay D, Rogers N, et al. Measurement properties of patient‐reported outcome measures for eczema control: a systematic review. J Eur Acad Dermatol Venereol. 2021;35(10):1987-93. https://doi.org/10.1111/jdv.17335

Rencz F, Szabó Á, Brodszky V. Questionnaire modifications and alternative scoring methods of the dermatology life quality index: a systematic review. Value Health. 2021;24:1158-71.

Heinl D, Prinsen C, Deckert S, Chalmers J, Drucker A, Ofenloch R, et al. Measurement properties of adult quality‐of‐life measurement instruments for eczema: a systematic review. Allergy. 2016;71(3):358-70. https://doi.org/10.1111/all.12806

Villela-Segura U, León-Dorantes G, Mercado-Lara A, Guevara-Sanginés E. Assessment of quality of life illness in adult patients with atopic dermatitis. Rev Med IMSS. 2021;59:306-12.

Sanclemente-Mesa G, Garcia H, Aguirre-Acevedo D, Jones-Caballero M, Lugo L, Escobar C. Reliability and construct validity of the Colombian version of the quality of life instrument Skindex-29 [C] in Medellin, Colombia/Fiabilidad y validez de constructo de la version colombiana del instrumento de calidad de vida Skindex-29 [C] en Medellin, Colombia/Fiabilidade e validade de constructo da versao Colombiana do instrumento de Qualidade de Vida Skindex-29 [C] em Medellin, Colombia. Iatreia. 2017;30(1):21-34.

Vasquez D, Aguirre D, Sanclemente G. Construct validity and responsiveness of the Colombian version of Skindex‐29. Br J Dermatol. 2019;181:770-7.

Armario-Hita J, Artimeb E, Vidal-Vilarc N, Hueteb T, Díaz-Cerezob S, Moro R, et al. Medidas de los resultados percibidos por el paciente en estudios de vida real en dermatitis atópica en España: revisión sistemática de la literatura. Actas DermoSifiliogr. 2022;113(7):685-704. https://doi.org/10.1016/j.ad.2022.01.025

Sanchez J, Cherrez-Ojeda I, Galvan C, Garcia E, Hernández-Mantilla N, Londoño Garcia A, et al. The unmet needs in atopic dermatitis control in Latin America: a multidisciplinary expert perspective. Dermatol Ther. 2021;11(5):1521-40. https://doi.org/10.1007/s13555-021-00595-9

Gooderham M, Hong C, Albrecht L, Bissonnette R, Dhadwal G, Gniadecki R, et al. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. J Cutan Med Surg. 2018;22(1 Suppl):3S-5S. https://doi.org/10.1177/1203475418803627

Samuel C, Cornman H, Kambala A, Kwatra S. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther. 2023;13:729-49.

Martinez-Cabriales S, Kirchhof M, Constantinescu C, Murguia-Favela L, Ramien M. Recommendations for vaccination in children with atopic dermatitis treated with Dupilumab: a consensus meeting, 2020. Am J Clin Dermatol. 2021;22:443-55.

Munshi MA, Noe MH, Chiu YE, Streicher JL. Vaccines: Considerations for pediatric dermatology patients on immunosuppressive agents. Pediatr Dermatol. 2021;38:1040-6.

Fan R, Cohen JM. Focus: Vaccines: Vaccination Recommendations for Psoriasis and Atopic Dermatitis Patients on Biologic Therapy: A Practical Guide. Yale J Biol Med. 2022;95:249.

Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I–systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409-31. https://doi.org/10.1111/jdv.18345

U.S Food & Drug Administration. Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death. 2021. Disponible en: https://t.ly/YtsFP

AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel; Chu D, Schneider L, Asiniwasis R, Boguniewicz M, De Benedetto A, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE–and Institute of Medicine–based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274-312. https://doi.org/10.1016/j.anai.2023.11.009

Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema–part II: non‐systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904-26. https://doi.org/10.1111/jdv.18429

Schünemann H, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa R, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol. 2017;81:101-10. https://doi.org/10.1016/j.jclinepi.2016.09.009